Hjem › Blærekreft › Tennessee
Kliniske studier for Blærekreft i Tennessee
34 studier for Blærekreft søker deltakere på steder i Tennessee.
Byer i Tennessee
Offisiell studietekst (engelsk)
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology PLLC, Nashville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06465069A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- SCRI Oncology Partners, Nashville
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06760819A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
- The Conrad Pearson Clinic ( Site 0143), Germantown
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06833073A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- SCRI Oncology Partners, Nashville
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06172478A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07090499Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
- The West Clinic - Wolf River, Germantown
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07061964Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
- SCRI Oncology Partners, Nashville
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT07566156Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Vanderbilt University/Ingram Cancer Center, Nashville
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT03866382Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
- Tennessee Oncology, PLLC - Chattanooga Downtown, Chattanooga
- Tennessee Oncology, PLLC - Chattanooga Med Park II, Chattanooga
- Tennessee Oncology, PLLC - Chattanooga Memorial, Chattanooga
- og 20 flere
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07421700A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
- Urology Associates, P.C., Nashville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07206225A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- Sarah Cannon Research Institute, Nashville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07277413DESTINY-PANTUMOUR04
- Research Site, Nashville
RekruttererObservasjonsstudie
Alder 18 til 130 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07124000A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
- The West Clinic, P.C. ( Site 0791), Germantown
- Thompson Cancer Survival Center ( Site 0803), Knoxville
- Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 0831), Nashville
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07419295A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Nashville
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07218380Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Sarah Cannon Research Institute, Nashville
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 18. sep. 2026 · NCT05267626A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
- SCRI, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 15. sep. 2026 · NCT07217171First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
- Sarah Cannon Research Institute, Nashville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 4. sep. 2026 · NCT06644755Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
- The Conrad Pearson Clinic (Urology America), Germantown
- Urology Associates, PC, Nashville
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 3. sep. 2026 · NCT06567743Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
- Conrad Person Clinic, Memphis
- Urology Associates PC, Nashville
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 24. aug. 2026 · NCT05951179FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- Sarah Cannon and HCA Research Institute, Nashville
- Tennessee Oncology, Nashville
- Vanderbilt University Medical Center, Nashville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 20. aug. 2026 · NCT05614739Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
- Research Site, Nashville
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 20. aug. 2026 · NCT07129993Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 18. aug. 2026 · NCT07097142A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 11. aug. 2026 · NCT05592626LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
- Urology Associates, P.C., Nashville
- Vanderbilt Univerity Medical Center, Nashville
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 7. aug. 2026 · NCT04752722Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
- Vanderbilt University Medical Center, Nashville
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 31. jul. 2026 · NCT07225127Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
- SCRI Oncology Partners, Nashville
- Local Institution - 0084, Nashville
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 29. jul. 2026 · NCT07106762A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- SCRI - TriStar Medical Group Children's Specialists, Nashville
- SCRI Oncology Partners, Nashville
RekruttererFase 2
Alder 8 og eldre · Alle kjønn · Oppdatert 27. jul. 2026 · NCT05503797An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
- Research Site, Nashville
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 22. jul. 2026 · NCT07720284A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- University of Tennessee Medical Center, Knoxville
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 22. jul. 2026 · NCT04879329A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- US Oncology Research LLC, Nashville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 6. jul. 2026 · NCT04389632Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
- Vanderbilt University Medical Center, Nashville
Rekrutterer
Alder 18 til 88 · Alle kjønn · Oppdatert 2. jul. 2026 · NCT06394869A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Vanderbilt University Medical Center, Nashville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 13. feb. 2026 · NCT06778863cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist (BHMCC), Memphis
- Vanderbilt-Ingram Cancer Center, Nashville
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 40 og eldre · Alle kjønn · Oppdatert 20. jan. 2026 · NCT05366881SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Memphis
- Massive Bio SYNERGY-AI site, Nashville
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.